Document is current

Article History

Received: 6 December 2022

Revised: 9 April 2023

Accepted: 19 April 2023

First Online: 5 May 2023

Competing interests

: All authors have completed the ICMJE uniform disclosure form. <b>T-V</b>: Abbvie: Consultancy; Novartis: Consultancy; Jazz: Consultancy, Speakers Bureau; Incyte: Consultancy, Speakers Bureau; CTI: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau. <b>AK</b>: Protagonist: Other: Research Support; Imago Biosciences: Consultancy, Honoraria, Speakers Bureau; Incyte: Consultancy, Honoraria, Speakers Bureau; Blueprint Medicines Corporation: Consultancy, Honoraria, Research Funding, Speakers Bureau; Novartis: Consultancy, Honoraria, Speakers Bureau; Abbvie: Consultancy, Honoraria, Speakers Bureau; GSK - Sierra Oncology: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Prelude Pharmaceuticals: Other: Research Support; BMS: Consultancy, Honoraria, Other: Research Support, Speakers Bureau; Morphosys: Other: Research Support; Pharmaessentia: Consultancy, Honoraria, Speakers Bureau; CTI Biopharma: Consultancy, Honoraria, Speakers Bureau. <b>KS</b>: Mablytics: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Pfizer: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Curis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; berGenBio: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Syntrix Pharmaceuticals: Research Funding; Incyte: Research Funding; AROG: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Gilead Sciences, Inc.: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Astellas: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees; Bristol Myers Squibb: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees. <b>JEL</b>: Novartis: Consultancy; Jasper Therapeutics: Consultancy; Dedham Group: Consultancy; Boxer Capital: Consultancy; Dava Oncology: Consultancy; Syntrix Pharmaceuticals: Research Funding; Astellas: Consultancy; Agios/Servio: Consultancy; Jazz: Consultancy; BerGenBio: Consultancy; Millenium Pharma/Takeda: Consultancy; ElevateBio Management: Consultancy; Daiichi Sankyo: Consultancy; Celgene/BMS: Research Funding; AbbVie: Consultancy; Servier: Consultancy. <b>EP</b>: Incyte: Research Funding; Kura: Research Funding; Stemline: Honoraria; Taiho: Honoraria; Blueprint: Honoraria; Syntrix Pharmaceuticals: Research Funding; BMS: Research Funding. <b>DAS</b>: Syntrix Pharmaceuticals: Research Funding; Nemucore: Membership on an entity’s Board of Directors or advisory committees; Lixte: Patents & Royalties: LB-100; Magenta: Consultancy; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Intellia: Membership on an entity’s Board of Directors or advisory committees; Syndax: Membership on an entity’s Board of Directors or advisory committees; Kite: Membership on an entity’s Board of Directors or advisory committees; Incyte: Speakers Bureau; Shattuck Labs: Membership on an entity’s Board of Directors or advisory committees; BMS: Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Aprea: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Agios: Membership on an entity’s Board of Directors or advisory committees; AbbVie: Membership on an entity’s Board of Directors or advisory committees; Takeda: Consultancy. <b>RSK</b>: Jazz: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; CTI biopharma: Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau; PharmaEssentia: Honoraria, Other, Speakers Bureau; BMS: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Abbvie: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Geron: Honoraria, Membership on an entity’s Board of Directors or advisory committees; Taiho: Honoraria, Membership on an entity’s Board of Directors or advisory committees. All other authors have no competing interests to declare.

: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by institutional review board and individual consent for this retrospective analysis was waived.